RxDoctor Payments DataLook up a doctor →

Michael Levine, MD

Nephrology · Los Angeles, CANPI 1740252048

Payments from drug & device makers

$866,600in general payments, 2019–2025

Across 1,054 payments — averaging $822.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$210K
  • Alnylam Pharmaceuticals Inc.$194K
  • CSL Behring$185K
  • AstraZeneca$134K
  • GSK$81K
  • Akebia Therapeutics Inc$31K
  • plus $31K from 54 others
$1,199in research payments, 2019–2025

Across 15 payments — averaging $79.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astrazeneca UK Limited7$209,820
Alnylam Pharmaceuticals Inc.18$194,225
CSL Behring67$185,146
AstraZeneca(2 entities)86$133,622
GSK44$81,442
Akebia Therapeutics Inc39$31,290
Gilead6$12,518
Amgen(2 entities)173$6,153
Daiichi Sankyo Inc.91$1,123
Calliditas Therapeutics US Inc.40$820
Bayer86$766
Boehringer Ingelheim31$736
Otsuka America Pharmaceutical, Inc.46$680
Ardelyx, Inc.42$669
Mallinckrodt Hospital Products Inc.30$666
Novartis29$639
Aurinia Pharma U.S., Inc.20$540
Lilly USA, LLC19$494
OPKO Pharmaceuticals, LLC28$447
Takeda Pharmaceuticals U.S.A., Inc.3$368
AbbVie(2 entities)14$362
Merck5$288
Johnson & Johnson10$258
Baxter Healthcare4$239
Mallinckrodt Enterprises LLC12$237
AMAG Pharmaceuticals, Inc.13$208
Pfizer9$200
Novo Nordisk8$179
Idorsia Pharmaceuticals US Inc4$170
Sanofi-aventis U.S. LLC3$162
Agios Pharmaceuticals, Inc.1$134
Amarin Pharma, Inc.2$131
Travere Therapeutics, Inc.7$130
Eisai Inc.2$127
Astellas Pharma US Inc1$125
Fresenius Kabi USA, LLC1$125
Jazz Pharmaceuticals Inc.1$120
EMD Serono, Inc.1$110
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$91
Nestle Healthcare Nutrition Inc.4$86
Stryker1$80
Regeneron Healthcare Solutions, Inc.3$78
Fresenius USA Marketing, Inc.3$74
IBSA Pharma Inc.3$71
Sumitomo Pharma America, Inc.3$63
Sanofi4$63
United Therapeutics Corporation1$60
Ultragenyx Pharmaceutical Inc.2$56
Exact Sciences3$55
Kyowa Kirin, Inc.2$53
La Jolla Pharmaceutical Company2$44
Arbor Pharmaceuticals, Inc.2$39
Shield Therapeutics Inc2$33
Ascendis Pharma Endocrinology Inc1$29
ANI Pharmaceuticals, Inc.2$28
Apellis Pharmaceuticals, Inc.1$26
Biohaven Pharmaceuticals, Inc.1$25
Vifor Pharma, Inc.2$24
Lexicon Pharmaceuticals, Inc.1$21
Shire North American Group Inc1$19

How this compares

$866,600 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California →

Medicare billing

Part B allowed, 2024
$448,401
Medicare patients
577
Services billed
14,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nephrology in Los Angeles

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →